NCT06422663

A Study To Evaluate The Treatment Pattern Of Moderate-to-Severe Asthma Patients In China

A Prospective, Observational, Multicentre Study To Evaluate The Treatment Pattern Of Moderate-to-Severe Asthma Patients In China

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 500 (actual)
• Sponsor: AstraZeneca · Industry
• Sex: All
• Age: 12 Years – 130 Years
• Healthy volunteers: Not accepted

Summary

This is a Prospective, Observational, Multicentre Study to describe treatment pattern changes of uncontrolled moderate-to-severe asthma patients in China. Sponsor by Astrazeneca Investment(China) Co., LTD.

Detailed description

This is a prospective, observational, multicentre study. Approximately 500 moderate-to-severe asthma patients from 30 sites across China. Patients will be treated following routine clinical practice. Study measures will be collected at week 0, week 12 and week 24. The primary objective of PRESENT study is to describe treatment pattern changes of uncontrolled moderate-to-severe asthma patients in China.

Conditions

• Moderate-to-Severe Asthma

Timeline

• Start date: 2024-03-22
• Primary completion: 2025-03-13
• Completion: 2025-03-13
• First posted: 2024-05-21
• Last updated: 2025-04-08

Locations

31 sites across 1 country: China